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The improvement of gene transfer efficiency in growth-arrested cells using human immunodeficiency virus type 1
(HIV-1)-derived vectors led to the development of vectors derived from other members of the lentivirus family. Here we report
the generation of a lentiviral vector derived from the apathogenic molecular virus clone SIVagm3mc of the simian
immunodeficiency virus from African green monkeys (Cercocebus pygerythrus). Upon pseudotyping with the G-protein of
vesicular stomatitis virus (VSV-G), the SIVagm-derived vector was shown to transduce proliferating and growth-arrested
mammalian cell lines, including human cells. After in vivo inoculation into the striatum of the adult rat brain, the vector was
shown to transduce terminally differentiated neurons and oligodendrocytes as well as quiescent and reactive astrocytes.
Moreover, SIVagm transfer vector mRNA was efficiently packaged by HIV-1 vector particles. Homologous [SIV(SIV)] vectors
generated by using the SIVagm-derived envelope glycoproteins allowed selective gene transfer into human CD41/CCR51
cells. Thus, the SIVagm3mc-derived vector is a useful alternative to HIV-1-derived lentiviral vectors in somatic gene therapy.
© 2001 Elsevier Science
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derived from onco-retroviruses similar to the ampho-
tropic murine leukemia virus (MLV-A) have often been
used. However, MLV-derived vectors require active pro-
liferation of the target cells for efficient transduction.
Growth-arrested or slowly dividing cells are only poorly
transduced. In contrast, vectors derived from lentiviruses
are capable of transducing nonproliferating cells (1) and
may thus be a useful alternative. Lentiviral vectors are
generated by triple transfection into mammalian cells of
plasmids harbouring the packaging (psi)-signal positive
transfer vector gene as well as the psi-negative lentiviral
gag/pol gene and a suitable psi-negative envelope gene
construct. For efficient transduction of human cells, the
G-protein of vesicular stomatitis virus (VSV-G) or the
MLV-derived envelope glycoproteins (Env) can be used
to generate pseudotype vector particles with a broad cell
tropism (2). Most often, human immunodeficiency virus
type 1 (HIV-1) has been used to derive lentiviral vectors.
As an alternative to the use of HIV-1-derived vectors,
other members of the lentivirus family have been used to
derive vectors, e.g., HIV-2 (3), simian immunodeficiency
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191virus (SIVmac) from rhesus macaques (Macaca mulatta;
Ref. 4, 5), or other nonprimate lentiviruses (6). We report
here the generation of a lentivirus vector derived from the
molecular clone SIVagm3mc of simian immunodefi-
ciency virus (SIVagm) from African green monkeys
(AGMs; Cercocebus pygerythrus). Following natural in-
fection as well as experimental inoculation, SIVagm has
been shown to be apathogenic in AGMs and in pig-tailed
macaques (Macaca nemestrina; Refs. 7, 8, 9-13). In ad-
dition, SIVagm belongs to a phylogenetically distinct
group of lentiviruses, which is very different from the
HIV-2/SIVsm/SIVmac or the HIV-1/SIVcpz group of lenti-
viruses. Therefore, we used the apathogenic molecular
virus clone SIVagm3mc to derive a new lentiviral vector
system.
Results and Discussion. SIVagm vectors can be
pseudotyped with VSV-G and packaged into HIV-1 vector
particles.
First we tested the ability of the SIVagm-derived pack-
aging construct S11b and the transfer vector S19-lacZ
(Fig. 1) to generate infectious vector particles upon co-
transfection with the VSV-G envelope construct MD-G
(14, 15) into 293T cells. As positive controls, HIV-1- and
MLV-derived vectors pseudotyped with VSV-G were pro-
duced accordingly. 293T cells transfected with the pack-
aging and transfer vector construct only, but not with an
envelope-encoding plasmid, served as negative con-
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192 RAPID COMMUNICATIONtrols. Furthermore, the capability of SIVagm- and HIV-1-
derived packaging constructs to cross-package the re-
spective heterologous vector genome RNA was tested
by transfection of the SIVagm-derived transfer vector
construct with the HIV-1-derived packaging construct,
and vice versa. Vectors were generated as described
and titrated in human 293 kidney cells and D17 canine
osteosarcoma cells (Table 1). As shown, infectious
SIVagm-derived vectors pseudotyped with VSV-G were
efficiently produced upon triple cotransfection of respec-
FIG. 1. Components of the SIVagm3mc-derived packaging system
Accession No. M30931) is given for comparison.
T
Cross-Packaging of Transfer Vectors b
Vector particle Transfer vector
[SIVagm(VSV-G)] SIVlacZ (pS19-lacZ)
HIVlacZ (pHR’CMV-lacZ)
MLVlacZ (pHIT110)
[HIV(VSV-G)] SIVlacZ
HIVlacZ
MLVlacZ
[MLV(VSV-G)] SIVlacZ
HIVlacZ
MLVlacZa Results from two independently performed experiments.tive plasmids and vector titers of 4 3 104 IU/ml or more
were measured in either one of the target cells. Transfer
of the SIVagm-derived packaging construct S11b into
target cells exposed to SIVagm-derived vector particles
was not observed, as tested by immunostaining of the
respective targeting cells using an anti-serum of a
SIVagm-infected pig-tailed macaque able to detect
SIVagm-Gag (Nem 170). This indicated that the deletion
in the psi-site was sufficient to avoid copackaging into
vector particles (data not shown). Absence of replication-
nvelope constructs. The genome structure of SIVagm3mc (GenBank
viral or Lentiviral Pseudotype Vectors
Vector titer in target cell [IU/ml]a
293 (human kidney) D17 (canine osteosarcoma)
9.2 3 104; 7.9 3 104 5.0 3 104; 3.7 3 104
8.0 3 102; 5.0 3 102 5.7 3 102; 4.0 3 102
,10; ,10 ,10; ,10
1.5 3 105; 2.4 3 104 3.1 3 104; 1.6 3 104
4.4 3 105; 1.4 3 106 9.8 3 104; 2.1 3 105
,10; ,10 ,10; ,10
,10; ,10 ,10; ,10
,10; ,10 ,10; ,10
1.1 3 106; 9.1 3 105 3.8 3 106; 1.6 3 106ABLE 1
y Retro
193RAPID COMMUNICATIONcompetent viruses in vector preparations was further
confirmed by the lack of reverse transcriptase (RT) activ-
ity in C8166 T cells, as determined with an assay specific
for lentiviral RTs (Cavidi Tech, Uppsala, Sweden) for 4
weeks of cultivation after transduction with both SIVagm-
and HIV-1-based pseudotype vectors (data not shown).
Replication of SIVagm used as a positive control with an
m.o.i. of 0.001 was readily detected. HIV-1-derived vec-
tors reached vector titers about five times higher than
those of SIVagm-based vectors. Interestingly, cross-
packaging of SIVagm- and HIV-1-derived transfer vectors
by the respective heterologous core particles was ob-
served (Table 1). Whereas the packaging of HIV-1-trans-
fer vectors into SIVagm core particles seemed to be
inefficient, resulting in low vector titers, encapsidation of
SIVagm3-derived vector genomes by HIV-1 core particles
led to high-titer vector preparations, indicating efficient
cross-packaging. This capability of vector components
derived from SIVagm and HIV-1 to allow formation of RNA
pseudotypes is consistent with the observed cross-pack-
aging between SIVmac and HIV-1 (4). The use of HIV-1-
derived packaging constructs and transfer vectors de-
rived from apathogenic SIVagm3mc may prove suitable
for the generation of lentiviral vectors with potentially
increased safety in humans, since the sequence homol-
ogy between these two vector components is further
minimised and makes recombination and generation of
replication competent lentiviruses less likely. In addition,
it is feasible to assume that cross-packaging of SIVagm-
derived vector genomes will lead to a further enhanced
inhibitory effect on HIV replication due to a TAR and RRE
decoy effect when used to transduce HIV-1-infected cells
(16). Therefore, this novel vector system may especially
contribute to future gene therapy strategies against
HIV-1 infection and AIDS.
SIVagm3 Vectors Efficiently Transduce Growth-
Arrested Cells. To test the capability of the SIVagm3mc-
derived vectors to transduce growth-arrested cells,
transduction experiments were performed using prolifer-
ating and growth-arrested human target cells in parallel.
Vector stocks were therefore generated as described
T
Transduction of Growin
Vector particle Transfer vector
[SIVagm(VSV-G)] SIVlacZ (pS19-lacZ)
[HIV(VSV-G)] HIVlacZ (pHR’CMV-lacZ)
[MLV(VSV-G)] MLVlacZ (pHIT110)
a Results from two independently performed experiments.and titrated in 293 cells. To achieve comparable trans-
duction efficacies, vector stocks were adjusted to 1 3105 IU/ml and again titrated in human 293 kidney cells
using serial dilutions. Growth arrest of target cells was
achieved by seeding cells 24 h prior to infection in
standard culture media containing 20 mg/ml of the DNA
polymerase inhibitor aphidicolin. Growth arrest in G1/S of
more than 97% of the cells was confirmed by FACS
analysis after propidium iodide staining as described
elsewhere (data not shown; Ref. 17). Two days posttrans-
duction, LacZ-positive cells were visualised by X-Gal
staining (Table 2). As expected, MLV-derived vectors
were not capable of transducing aphidicolin-treated
cells. In contrast, SIVagm- and HIV-1-derived vector par-
ticles mediated gene transfer into growth-arrested cells
with comparable efficiencies. Obtained transduction ef-
ficiencies in growth-arrested cells ranged between 20
and 40% for the SIVagm-derived vectors and 40 and 80%
for the HIV-1-based vector particles, compared to the
respective titers in proliferating target cells. These re-
sults clearly demonstrate the ability of vector particles
derived from apathogenic SIVagm3mc to enable the
transduction of growth-arrested human cells. This prop-
erty is believed to be crucial for successful gene delivery
in vivo in future gene therapy applications (15).
SIVagm Vectors are Capable of Transduction of Neu-
ronal and Glial Cells In Vivo. Adult female Fischer 344
rats (n 5 5, injection sites n 5 10) were anesthesised (44
mg/kg ketamine, 0.75 mg/kg acepromazine, 4mg/kg xy-
lazine, in 0.9% NaCl ip) and 3 ml of an [SIVagm(VSV-G)]
vector preparation generated by cotransfection of 293T
cells with pS11b, pS19-lacZ, and pMD-G followed by
concentration via ultracentrifugation to 3 3 106 IU/ml
was injected into the striatum (AP 1 0.2, ML 6 3.5, DV 2
4.5) bilaterally using a 5-ml Hamilton syringe (15, 18, 19).
After 4 weeks, animals were sacrificed and analysed for
b-Gal-positive cells in the striatum (Fig. 2). All adult rat
brain injection sites showed expression of the trans-
gene. No inflammatory reaction was noticed. Immunoflu-
orescent staining with a rabbit polyclonal antibody
against b-Gal revealed transduction of different cell
types of the central nervous system. Counterstaining for
cell-specific markers, such as NeuN for terminally differ-
Growth-Arrested Cells
Vector titer in 293 target cells [IU/ml]a
Growing Growth-arrested
9.8 3 104; 9.8 3 104 2.1 3 104; 4.0 3 104
1.1 3 105; 9.8 3 104 8.8 3 104; 4.4 3 104
1.2 3 105; 1.1 3 105 6 3 101; ,10ABLE 2
g andentiated neurons, GFAP for astrocytes, and Rip for oligo-
dendrocytes, showed that the vectors transduced neu-
, Cy3 5
ITC 5 g
cal sc
194 RAPID COMMUNICATIONrons (Figs. 2A1–A3), astrocytes (Figs. 2B1–B3), and oli-
godendrocytes (Fig. 2C1–C3). The capability of
[SIVagm(VSV-G)] vectors to transduce a variety of cells in
the adult rat brain was thus demonstrated and is in
accordance with previous findings using other lentiviral
vectors (18, 20, 21).
SIVagm Vectors Are Capable of Selectively Transduc-
ing CD41 Cells Upon Pseudotyping with Variants of the
FIG. 2. Transduction of neuronal and glial cells in vivo. High magnific
following lentiviral gene transfer. Staining with NeuN for terminally di
overlap in striatal medium spiny neurons (A1). GFAP for astrocytes (B3
astrocytes (B1). RIP for oligodendrocytes (C3) and b-Gal staining (C2, F
The overlay in the first row projected double labeling in a single confoHomologous and Heterologous Lentiviral Envelope Gly-
coproteins. HIV-1-derived vectors have been designed totransfer therapeutic genes selectively into human cell
types permissive for HIV-1 infection (16). Such HIV-1
vector particles use their natural envelope glycoproteins
for entry and thus display the CD4-dependent cell tro-
pism known from wild-type HIV-1. Although the resulting
vector titers are relatively low compared to those of
lentiviral vectors pseudotyped with the VSV-G envelope,
these vectors may prove useful for the establishment of
of striatal injection sites are shown, presenting b-Gal-expressing cells
ated neurons (A3, Cy3 5 red) and b-Gal (A2, FITC 5 green) showed
red) and b-Gal staining (B2, FITC 5 green) revealed coexpression in
reen) showed oligodendrocytes stably expressing the transgene (C1).
anned area (A1, B1, C1).ations
fferentian in vivo gene therapy against HIV-1 infection and AIDS,
as selective delivery of therapeutic genes into the host
195RAPID COMMUNICATIONcells of HIV-1 may be achievable. Major drawbacks of
these vectors may be the expected fast neutralisation by
HIV-1-specific antibodies in HIV-1-infected patients and
the very likely further decreased vector titer when genes
are transferred that inhibit the replication of HIV-1, such
as ribozymes, RNA decoys, and single-chain antibodies
(scFv) directed against conserved HIV-1 sequences or
epitopes, respectively. Assuming that these inhibitory
genes interfere with the viral vector components, it is
very likely that this will have a negative impact on vector
titers. As SIVagm is only poorly neutralised by sera from
HIV-1-infected patients (22) and is only distantly related
to HIV-1, such inhibitory effects are not expected using
SIVagm-derived vector particles displaying the homolo-
gous envelope glycoproteins. We therefore wanted to
test the possibility of generating SIVagm-derived vectors
displaying their natural CD4-dependent tropism. Thus,
293T cells were cotransfected with the packaging con-
struct S11b, the plasmid pS19-lacZ harbouring the trans-
fer vector, and the envelope construct Rep D10 env (Fig.
1) encoding a C-terminally truncated variant of the trans-
membrane protein and the full-length surface envelope
glycoprotein of SIVagm3mc (22). The resulting [SIV(SIV)]
vectors were expected to mediate cell entry into CD41/
CCR51 and CD41/Bonzo1 cells. [HIV(HIV)] vectors bear-
ing a similarly modified envelope derived from HIV-1
(designated as Tr712; Ref. 23) served as controls. Enve-
lope construct Tr712 has been derived from a T-cell
tropic HIV-1-strain mediating specific infection of CD41/
CXCR41 cells. Furthermore, hybrid vectors [HIV(SIV)] and
[SIV(HIV)] were generated by cotransfection of 293T cells
with pCMVDR8.2, pHR9CMV-lacZ, and pRepD10env, or
with pS11b, pS19-lacZ, and Tr712, respectively. The cell-
free supernatants of the transfected 293T cells were
subsequently used to transduce derivatives of the
megaglioma cell line U87 expressing human CD4 and
one of the coreceptors CCR5 or CXCR4 (24), respectively.
X-Gal staining performed 2 days posttransduction re-
vealed selective and efficient transduction of the CD4/
CCR5-expressing target cells by SIVagm-derived vectors
T
Coreceptor Usag
Vector particle Transfer vector Envelope
[SIVagm(SIVagm)] SIVlacZ pRepSIVa
[HIV(HIV)] HIVlacZ pHIV-1 Tr7
[SIVagm(HIV)] SIVlacZ pHIV-1 Tr7
[HIV(SIVagm)] HIVlacZ pRepSIVa
a Results from two independently performed experiments.and the [HIV(SIV)] hybrid vectors, as indicated in Table 3.
In contrast, only CD41/CXCR41 cells were transduced by[HIV(HIV)] vectors or [SIV(HIV)] hybrid vectors, both dis-
playing the envelope glycoprotein variants of T-cell tropic
HIV-1. The titers of up to 1.6 3 104 IU/ml obtained for the
[SIV(SIV)] or [HIV(HIV)] vectors were comparable to those
mentioned in previous reports (25). The titers of the
respective [SIV(HIV)] and [HIV(SIV)] vectors were about
5 3 103 to 4 3 104 IU/ml and thus lower but sufficient for
the determination of the respective coreceptor usage.
The 10-fold lower titer of [HIV(SIV)] vectors detected in
CD41/CXCR41 U87 cells was higher than expected.
However, it was assumed that this may have resulted
from a background of Bonzo expression in U87 cells. In
summary, these observations showed that selective
gene transfer into human CD41/CCR51 cells is achieved
using [SIV(SIV)] vectors carrying the envelope glycopro-
teins of SIVagm3mc. To exclude rapid generation of rep-
lication-competent virus during vector preparation, an
assay similar to that described above was performed.
Following transduction of C8166 T cells with each of the
vectors listed in Table 3 and subsequent cultivation of
the respective cells for another 4 weeks, no RT activity
was detected (data not shown). Thus, using such enve-
lope mutants, these vectors derived from apathogenic
SIVagm3mc should be able to circumvent the major
drawbacks of HIV-1-based vectors.
Materials and Methods. Vector components. Expres-
sion constructs used for the generation of vectors are
shown in Fig. 1. Details of the construction are available
from the authors upon request. Briefly, the packaging
construct S11b encompasses the functional genes gag/
pol, vif, vpx, tat, and rev. The env gene was truncated to
a final extent of only 1035 nt of originally 2631 nt by
inserting a stop codon at nt position 6809. The putative
packaging signal psi (C) was removed by deleting a
19-nt fragment (nt 334–353). The 59LTR was replaced by
a CMV promoter, whereas the 39LTR was substituted by
the polyadenylation signal [p(A)] of the bovine growth
hormone gene (BGH). The transfer vector S19-lacZ con-
tains the flanking LTRs of SIVagm3mc, the rev-respon-
entiviral Vectors
uct
Vector titer in U87-derived target cells
expressing HIV receptors [IU/ml]a
CD41/CCR51 CD41/CXCR41
env 7.7 3 103; 7.7 3 103 ,10; ,10
,10; ,10 1.2 3 104; 1.6 3 104
,10; ,10 4.7 3 103; 5.9 3 103
env 4.2 3 104; 5.2 3 103 5.8 3 102; 3.5 3 103ABLE 3
e of L
constr
gmD10
12
12
gmD10sive element (RRE), and the splice donor (SD) and ac-
ceptor (SA) of SIVagm3mc, as indicated. The first 1559 nt
196 RAPID COMMUNICATIONof the gag gene were included but transcription was
abrogated by deleting the start codon. The lacZ reporter
gene is driven by a CMV promoter. The envelope con-
struct pMD-G was used to pseudotype all vector parti-
cles described here with VSV-G. The envelope con-
structs pTr712 and pRepSIVagmD10env have been pre-
viously described (22) and encompass truncated variants
of the envelope genes derived from T-cell tropic HIV-1
and SIVagm3mc driven by the human b-actin promoter
and the 39LTR of Rous sarcoma virus (RSV), respectively.
Generation of Vector Particles and Infection of Target
Cells. SIVagm3-derived constructs were designed to al-
low generation of the vectors by cotransfection of three
plasmids into 293T cells. The transfer vector harbouring
the reporter gene lacZ, the packaging construct encom-
passing the lentiviral genes (gag/pol, vif, vpx, tat, and
rev), and the VSV-G encoding gene were located on three
separate plasmids (Fig. 1). Packaging constructs and
transfer vectors derived from HIV-1 (pCMVDR8.2 and
pHR9CMV-lacZ; ref. 15) and MLV (pHIT60 and pHIT110;
Ref. 26) served as controls. Vector particles were gener-
ated by lipofection of 5 3 105 293T cells using the
reagent Lipofectamin P (Gibco, Eggenstein, Germany)
according to the manufacturer’s instructions. Forty-eight
hours posttransfection cell culture supernatants were
freed from contaminating cells by passaging through a
0.45-mm filter and subsequently used in various dilutions
to infect 2 3 105 target cells in a total volume of 1 ml.
After 2 h of coincubation of cells and vector particles,
target cells were washed and expanded. All cells were
cultured using DMEM (Gibco) supplemented with 10%
fetal calf serum (FCS, Seromed, Berlin, Germany). Deter-
mination of vector titers was performed by X-Gal assay
and counting of b-Gal-positive cells.
Analysis of Rat Brains for Expression of b-Galactosi-
dase. Animals were perfused intracardially with saline,
4% paraformaldehyde, and 0.2% glutaraldehyde. The
brains were removed, postfixed, and saturated in 30%
sucrose. Brains were frozen sectioned on a sliding mic-
rotome into 50-mm slices. Primary antibodies (Ab) used
for immunohistochemistry were incubated overnight at
4°C in the following dilution: rabbit AB against b-galac-
tosidase (Cortex, 1:10,000), mouse Ab against NeuN de-
tecting terminally differentiated neurons (Chemi-Con,
1:500), guinea pig Ab (Advanced Immunochemicals,
1:250), or mouse Ab against GFAP (Chemi-Con, 1:1000)
detecting astrocytes and mouse Ab against Rip-detect-
ing oligodendrocytes (Chemi-Con, 1:20,000). Corre-
sponding fluorescent-coupled secondary antibodies
(Cy3, FITC, Jackson, 1:250) were used and nuclear stain-
ing was achieved by diamidino-2-phenylindole (Molecu-
lar Probes). The sections were analysed by confocal
scanning laser microscopy (Leica). The signals were
collected, digitally colour enhanced, and superimposed
with Photoshop 5.0 (Adobe Photoshop).ACKNOWLEDGMENTS
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